Full-Time

Senior Director Toxicology

Toxicology, CNS Specialist

Centessa Pharmaceuticals

Centessa Pharmaceuticals

51-200 employees

Clinical-stage pharma with asset-centric model

Compensation Overview

$250k - $270k/yr

+ Discretionary Annual Bonus

Boston, MA, USA

Remote

Remote US-based role with regular travel up to 25-30%.

Category
Biology & Biotech (1)
Required Skills
Pharmacology

Get referred to Centessa Pharmaceuticals

See people who can refer or advise you

Requirements
  • PhD in Toxicology, Pharmacology, Pathology, Neuroscience, DVM, or related discipline; board certification (e.g., DABT, ERT).
  • 12+ years of pharmaceutical or biotechnology R&D experience with a strong track record in nonclinical and regulatory toxicology, including substantial experience supporting CNS / neuroscience drug development (required).
  • Deep expertise supporting small molecule programs across discovery, IND-enabling, and early clinical development, with demonstrated experience advancing CNS-active candidates.
  • Demonstrated experience serving as the toxicology lead on cross-functional drug development programs.
  • Extensive experience authoring and reviewing nonclinical sections of global regulatory submissions (IND/CTA/IB/DSUR/NDA) and preparing written responses to health authority inquiries.
  • Strong working knowledge of FDA, EMA, and ICH guidance documents and GLP regulations, with a solid understanding of how QA, regulatory, and clinical functions interface with nonclinical safety assessment.
  • Demonstrated success leading outsourcing and oversight of toxicology and safety pharmacology studies and managing CRO study directors and partnerships.
  • Strong ability to integrate complex nonclinical datasets across toxicology, pathology, DMPK, and pharmacology to inform development decisions.
  • Proven ability to work independently, set priorities, and deliver high-quality program output without close supervision, while collaborating effectively with peers across functions.
  • Excellent verbal communication and scientific writing skills as applied to study reports and regulatory documents.
  • Sense of urgency, detail orientation, and ability to thrive in a hands-on, growth stage environment.
Responsibilities
  • Define and execute nonclinical safety strategies for assigned small molecule CNS programs across discovery, IND-enabling, and clinical development stages.
  • Develop safety strategies for new CNS targets, lead optimization programs, and platform technologies.
  • Proactively identify gaps and emerging risks within assigned programs and implement risk mitigation plans, engaging external experts as appropriate.
  • Maintain a current understanding of scientific literature and regulatory guidance relevant to CNS toxicological assessment, and sustain a professional network of external subject matter experts to inform program strategy.
  • Design, oversee, and interpret GLP, non-GLP, investigative, and in vitro toxicology and safety pharmacology studies, with emphasis on endpoints and models relevant to CNS-active small molecules.
  • Lead outsourcing efforts for the design, monitoring, execution, and reporting of nonclinical toxicology studies, ensuring scientific quality, regulatory compliance, and timely delivery.
  • Manage and monitor outsourced toxicology and safety pharmacology studies at external CROs, interacting effectively with CRO study directors throughout study conduct.
  • Critically review and edit nonclinical study reports and coordinate report finalization with CROs.
  • Integrate complex nonclinical datasets across toxicology, pathology, DMPK, and pharmacology to inform candidate selection and program decisions.
  • Author and critically review the toxicology sections of global regulatory documents, including pre-IND packages, INDs, CTAs, IBs, DSURs, and NDA submissions.
  • Prepare science-based written responses to nonclinical inquiries from health authorities (FDA, EMA, and other global regulators).
  • Collaborate closely with peers in biology, DMPK, pathology, pharmacology, clinical, regulatory, and CMC to ensure toxicology activities and findings are integrated into overall program plans.
  • Provide day-to-day scientific direction and mentorship to entry-level toxicology staff supporting assigned programs.
  • Work independently to plan, prioritize, and deliver on program toxicology objectives.
Centessa Pharmaceuticals

Centessa Pharmaceuticals

View

Centessa Pharmaceuticals uses an asset-centric hub-and-spoke model formed from ten subsidiary companies to advance multiple therapies. Its lead program ORX750 is an oral orexin receptor 2 agonist for sleep-wake disorders and is in Phase 2a with Phase 2 data expected in 2025. It also develops an early-stage immuno-oncology program based on the LockBody technology, which engineers antibodies to improve cancer treatment. The company funds development through equity, debt, and partnerships and aims to move ORX750 toward regulatory approval while expanding its oncology portfolio.

Company Size

51-200

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2021

Get referred to Centessa Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ORX750 has Phase 2a data expected across three sleep indications in 2025.
  • ORX489 and ORX142 expand the orexin pipeline beyond one lead asset.
  • Clinical proof-of-concept could support registrational trials and partnering interest.

What critics are saying

  • ORX750 depends on a single Phase 2a readout for franchise validation.
  • Late-stage sleep-disorder competitors can outspend Centessa and capture prescriber attention.
  • LockBody remains unproven clinically and offers no near-term commercial backstop.

What makes Centessa Pharmaceuticals unique

  • Asset-centric subsidiaries accelerate Centessa's focused orexin and oncology development.
  • ORX750 targets NT1, NT2, and idiopathic hypersomnia with oral dosing.
  • LockBody® adds a separate immuno-oncology platform beyond neuroscience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Telework isn't listed but Remote Work Options covers it

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-3%
American Academy of Sleep Medicine
Jul 19th, 2026
Talking sleep | live from SLEEP 2026.

Talking sleep | live from SLEEP 2026. Season 8 | episode 12. In this special live episode recorded from the SLEEP 2026 annual meeting in Baltimore, host Dr. Seema Khosla welcomes Dr. Sanjay Patel, director of the clinical sleep program at University of Pittsburgh Medical Center, to discuss groundbreaking medications for sleep disorders poised for FDA approval in 2026 and 2027. The pharmaceutical landscape for sleep medicine is undergoing unprecedented transformation. Dr. Patel surveys the emerging drug pipeline that will fundamentally change how clinicians treat obstructive sleep apnea, narcolepsy, and idiopathic hypersomnia. For obstructive sleep apnea, Dr. Patel discusses AD-109 (atomoxetine and R-oxybutynin), explaining the mechanistic rationale and practical considerations including use with tirzepatide. The Incannex drug combining dronabinol and acetazolamide receives analysis for different patient populations, and sultiame is discussed as a carbonic anhydrase inhibitor option. A critical framework emerges: Should treatment be symptom-based or airway-focused when PAP-intolerant patients present? Tirzepatide, the GLP-1 agonist FDA-approved for moderate-to-severe OSA, receives comprehensive coverage including muscle loss concerns, long-term use, and emerging oral GLP-1 options. Retatrutide, the triple-hormone agent combining GLP-1, GIP, and glucagon, is also discussed. The episode's most exciting segment focuses on orexin agonists for narcolepsy. Three pharmaceutical companies - Alkemeres, Centessa (purchased by Lilly), and Takeda - are developing these mechanistically novel agents. Dr. Patel clarifies how these medications differ, discusses why one medication disrupted nocturnal sleep (suggesting continued roles for oxybates), and addresses how clinicians will choose between similar medications. Dr. Patel emphasizes a fundamental question: Should the field prioritize symptom management versus airway patency for OSA, and mechanistic approaches versus symptom management for narcolepsy? Whether you're interested in emerging OSA treatments, narcolepsy innovations, or the future of pharmacological sleep medicine, this live episode provides essential updates on medications that will soon reshape clinical practice. Join American Academy of Sleep Medicine for this exciting conversation about how sleep medicine will transform in the coming years. Dr. Sanjay R. Patel, an expert in sleep health, is certified in pulmonary disease and sleep medicine by the American Board of Internal Medicine. Dr. Patel is a professor of medicine and epidemiology at University of Pittsburgh, and medical director of UPMC Comprehensive Sleep Disorders program. He earned a master's degree in epidemiology from the Harvard School of Public Health and a medical degree from Harvard Medical School and Massachusetts Institute of Technology. He completed a residency at the University of Pennsylvania Health System and a fellowship at Massachusetts General Hospital. Dr. Patel's research focuses on the health implications of poor sleep with particular interest on the relationships between sleep and cardiometabolic disease. He directs the Center for Sleep and Cardiovascular Outcomes Research at the University of Pittsburgh. He has published extensively on the subject of obesity management and glucose metabolism with sleep apnea, as well as the association between curtailed sleep and long-term health effects.

Genetic Engineering and Biotechnology News
Apr 10th, 2026
Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge.

Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge. April 10, 2026 From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab. Its editors discuss the latest autonomous systems accelerating biological discovery. In business deals, Gilead Sciences has acquired Tubulis in a transaction worth up to $5 billion, strengthening the buyer's position in antibody-drug conjugates for cancer. Correspondingly, Eli Lilly and Biogen are each making billion-dollar-plus bets, acquiring Centessa, a sleep disorder drug developer, and Apellis, known for its work in immunology and rare diseases. Its episode rounds out by unpacking the dynamic obesity drug market, where intensifying competition from Novo Nordisk's Wegovy pill is prompting Lilly to temper the 2026 sales outlook for its oral obesity drug, Foundayo. Listed below are links to the GEN stories referenced in this episode of Touching Base:

BioSpace
Mar 31st, 2026
Lilly wakes up sleep market with $6.3B Centessa buy to challenge Takeda.

Lilly wakes up sleep market with $6.3B Centessa buy to challenge Takeda. March 31, 2026 | In the buyout, Eli Lilly picks up Centessa Pharmaceuticals' lead asset cleminorexton, which could go toe-to-toe with Takeda's oveporexton, currently under FDA review with a decision expected in the third quarter. Looking to further expand its expertise beyond the cardiometabolic and neurology arenas, Eli Lilly is taking over Centessa Pharmaceuticals and its pipeline of sleep disorder drugs - a move that could put the pharma in direct competition with Takeda. Under the terms of the acquisition agreement, announced Tuesday morning, Lilly will snap up Centessa for $38 per share or $6.3 billion upfront. The pharma has also offered a contingent value right that entitles stockholders to $9 more per share if the deal hits certain milestones, including one of two FDA approvals before a certain period of time lapses. This contingent offer could add $1.5 billion more to the total buyout value. Lilly and Centessa expect to close the transaction in the third quarter of 2026. The boards of directors of both companies have approved the deal. At the heart of the acquisition agreement is Centessa's lead asset cleminorexton, an oral orexin receptor 2 (OX2R) agonist being trialed for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Orexin is a key neuropeptide that regulates the sleep-wake cycle, according to the biotech's website, in turn promoting wakefulness. Drugs that activate this pathway could help address excessive daytime sleepiness as well as improve attention, cognition and fatigue. In April 2025, Centessa released Phase 1 data showing that a 5-mg oral dose of cleminorexton delayed sleep by an average of 37.9 minutes compared to 15.3 minutes in placebo recipients, resulting in a "statistically significant" treatment effect of 22.6 minutes, the biotech said at the time. This readout "reinforces ORX750 as a potentially best-in-class OX2R agonist relative to competitors," Leerink analysts wrote an April 7, 2025 note. Analysts at BMO Capital Markets said Centessa's orexin receptor agonist has "best-in-class" potential for narcolepsy, putting the company in a strong position in the $15 billion market. April 7, 2025 With the Centessa pickup, Lilly will go toe-to-toe with Takeda, which is far ahead in the narcolepsy race with its late-stage oveporexton, also an OX2R agonist. In July 2025, Takeda announced that oveporexton significantly improved excessive daytime sleepiness, attention, quality of life, functioning and cataplexy in two Phase 3 studies. The FDA accepted Takeda's approval submission for the candidate last month, with a decision out in the third quarter of this year. Also in the narcolepsy game is Alkermes, which in November last year announced that its own OX2R agonist alixorexton aced Phase 2 and would move into late-stage development. The drug improved wakefulness and eased daytime sleepiness in patients with narcolepsy type 2, according to results presented at the time. Alixorexton's Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2. November 13, 2025 Aside from cleminorexton, Lilly will also come into possession of Centessa's broader pipeline of OX2R agonists, which includes additional preclinical assets with therapeutic potential "across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions," the pharma said Tuesday. Tristan is BioSpace 's senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. He can be reached at [email protected], [email protected] or on LinkedIn.

PR Newswire
Mar 31st, 2026
Lilly to acquire Centessa for $6.3B to advance sleep-wake disorder treatments

Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38.00 per share in cash plus contingent value rights worth up to $9.00 per share, valuing the deal at approximately $6.3 billion upfront with potential additional payments of $1.5 billion. The upfront consideration represents a 40.5% premium to Centessa's 30-day volume-weighted average share price. Centessa is developing orexin receptor 2 agonists for sleep-wake disorders, with lead candidate cleminorexton showing promising results in Phase 2a studies across narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. The acquisition expands Lilly's neuroscience portfolio into sleep medicine. Contingent payments are tied to FDA approvals of cleminorexton or ORX142 by 2030. The transaction, structured as a scheme of arrangement, requires shareholder approval and is expected to close in the third quarter.

BioWorld
Mar 31st, 2026
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy.

Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy. March 31, 2026 Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights, gaining access to a pipeline of orexin receptor 2 (OX2R) agonists for sleep disorders. The pharma is re-entering a field that has multibillion-dollar potential and one that could emulate the success seen with its obesity program. Centessa, of Boston and London, has a lead candidate, ORX-750, with positive phase IIa data in narcolepsy types 1 and 2 and idiopathic hypersomnia, as well as two other OX2R agonists: ORX-142 for neurological and neurodegenerative disorders, and ORX-489 for neuropsychiatric disorders. The M&A, expected to close in the third quarter, boosted not only Centessa's shares (NASDAQ:CNTA) - which rose 45% to $39.99 in early trading March 31 - but also competitor Alkermes plc's shares (NASDAQ:ALKS), up 17% to $35.41 midday, as it has a similar candidate in development. Biogen paying $5.6B for Apellis; cvrs, too. Biogen Inc. and Apellis Pharmaceuticals Inc. inked a deal whereby the former has agreed to acquire all outstanding shares of the latter for $41 each, or about $5.6 billion. Apellis stockholders will also take ownership of a nontransferable contingent value right for each Apellis share held, entitling the holder to bank two payments of $2 per share if annual global net sales thresholds are met with Syfovre (pegcetacoplan), Apellis' complement inhibitor approved by the U.S. FDA in February 2023 for geographic atrophy secondary to age-related macular degeneration. Shares of Apellis (NASDAQ:APLS) were trading at $40.28, up $23.19, or 135%. Biogen (NASDAQ:BIIB) was selling for $178.99, down $8.58. Galapagos rebrands, moves forward in autoimmune diseases. Galapagos NV is about to bury its recent turbulent past and sail off for the future with its near €3 billion cash pile and the new name of Lakefront Biotherapeutics NV. The foundation for the transition was laid earlier this month in an arrangement with Gilead Sciences Inc., holder of 25% of Galapagos' equity, to "co-parent" the assets of Ouro Medicines LLC, which Gilead is acquiring up to $2.17 billion. On March 31, Galapagos confirmed details of the deal, under which it will conduct further development of Ouro's lead asset, gamgertamig (OM-336), a bispecific T-cell engager antibody that is in phase Ib dose-ranging studies in a number of rare autoimmune diseases. Simcere's rademikibart meets phase III endpoints in atopic dermatitis. Simcere Pharmaceutical Group Ltd.'s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis (AD). The company presented results of the phase III Radiant-AD study at the American Academy of Dermatology meeting in Denver on March 30. As previously reported by BioWorld, Simcere entered an exclusive licensing and collaboration agreement with Connect Biopharma Holdings Ltd., obtaining rights to develop, manufacture and commercialize rademikibart for all indications in China. Whoop secures $575M, with abbott a strategic investor. Whoop Inc. secured $575 million in a series G funding round at a $10.1 billion valuation to advance its AI-powered wearable platform for personalized and preventive health care. Abbott Laboratories joined the round as a strategic investor, backing the company's push to expand access to its device amid growing demand. Braveheart finds phase II positive for cardiac myosin inhibitor. Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology's Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study. BHB-1893 is an oral cardiac myosin inhibitor that Braveheart licensed from Jiangsu Hengrui Pharmaceuticals Co. Ltd. in September 2025 for $65 million up front and up to $1.01 billion in development and sales milestone payments, plus royalties. US FDA says no, again, to Vanda's tradipitant in gastroparesis. The path forward, at least in the U.S., is getting narrower for Vanda Pharmaceuticals Inc.'s tradipitant as a treatment for gastroparesis, a serious disorder for which there's been no new treatment for several decades. Sara Brenner, the principal deputy FDA commissioner, denied Vanda's request for an agency hearing on CDER's proposal to refuse to approve the drug for that indication. "I find that there is no genuine and substantial issue of fact justifying a hearing," Brenner said in issuing an order refusing to approve the NDA. Vanda's recourse, she noted, is to submit a petition for reconsideration to the FDA commissioner. Supreme Court shuts the door to three life sciences petitions. What do a patent dispute over a CRISPR-Cas system, a rejected whistleblower case involving lab tests and a vaccine injury claim parading as multidistrict tort litigation have in common? All three were denied cert in the U.S. Supreme Court's latest orders list. Consequently, two Agilent Technologies Inc. patents relating to a CRISPR-Cas system for gene editing will remain invalid. A former Quest Diagnostics Inc. employee can't move forward with her fourth amended qui tam complaint against the company. And the multidistrict Gardasil liability litigation against Merck & Co. has hit the end of the road. Also in the news. 4DMedical, Adarx, Alamar, Alumis, Anaptysbio, Anumana, AP Biosciences, Arch, Arcutis, Arrowhead, Artelo, Aurinia, Biocytogen, Biogen, Biomx, BMS, Boston Scientific, Bridgebio, Butterfly, Castle, Cathworks, Centivax, Chiesi, Connect, Cue, Egetis, Eisai, Elevar, Enodia, Everest Medicines, First Tracks, GSK, Idorsia, Incyte, Inflarx, Innovent, J&J, Kailera, Kardigan, Kezar, Konica Minolta, Kymera, Levicept, Medtronic, Merck, Moonlake, Nanoscope, Novavax, Oncomatryx, Pie Medical, Priovant, Radiant Vision, Roche, Royalty Pharma, Sanofi, Savara, Simcere, Sobi, SS Innovations, Taisho, Takeda, Tasly, Teva, Transcenta, United, Viridian, Zymeworks To read more on related topics, click on one of the words below.